首页> 外文期刊>Journal of the American College of Surgeons >Beta-blockers in isolated blunt head injury.
【24h】

Beta-blockers in isolated blunt head injury.

机译:β-受体阻滞剂在孤立的钝性颅脑损伤中。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: The purpose of this study was to evaluate the effect of beta-blockers on patients sustaining acute traumatic brain injury. Our hypothesis was that beta-blocker exposure is associated with improved survival. STUDY DESIGN: The trauma registry and the surgical ICU databases of an academic Level I trauma center were used to identify all patients sustaining blunt head injury requiring ICU admission from July 1998 to December 2005. Patients sustaining major associated injuries (Abbreviated Injury Score > or = 4 in any body region other than the head) were excluded. Patient demographics, injury profile, Injury Severity Score, and beta-blocker exposure were abstracted. The primary outcomes measure evaluated was in-hospital mortality. RESULTS: During the 90-month study period, 1,156 patients with isolated head injury were admitted to the ICU. Of these, 203 (18%) received beta-blockers and 953 (82%) did not. Patients receiving beta-blockers were older (50 +/- 21 years versus 38 +/- 20 years, p < 0.001), had more frequent severe (Abbreviated Injury Score > or = 4) head injury (54% versus 43%, p < 0.01), Glasgow Coma Scale < or = 8 less often (37% versus 47%, p = 0.01), more skull fractures (20% versus 12%, p < 0.01), and underwent craniectomy more frequently (23% versus 4%, p < 0.001). Stepwise logistic regression identified beta-blocker use as an independent protective factor for mortality (adjusted odds ratio: 0.54; 95% CI, 0.33 to 0.91; p = 0.01). On subgroup analysis, elderly patients (55 years or older) with severe head injury (Abbreviated Injury Score > or = 4) had a mortality of 28% on beta-blockers as compared with 60% when they did not receive them (odds ratio: 0.3; 96% CI, 0.1 to 0.6; p = 0.001). CONCLUSIONS: Beta-blockade in patients with traumatic brain injury was independently associated with improved survival. Older patients with severe head injuries demonstrated the largest reduction in mortality with beta-blockade.
机译:背景:本研究的目的是评估β受体阻滞剂对急性颅脑外伤患者的作用。我们的假设是,β-受体阻滞剂的暴露与生存率提高有关。研究设计:1998年7月至2005年12月,使用了I级学术创伤中心的创伤登记和外科ICU数据库来确定所有需要接受ICU入院的所有遭受钝性颅脑损伤的患者。遭受重大相关伤害的患者(缩写伤害评分>或=在除头部以外的任何身体区域中排除了4个)。摘录了患者的人口统计资料,损伤概况,损伤严重程度评分和β受体阻滞剂暴露量。评估的主要结局指标是院内死亡率。结果:在90个月的研究期内,有1,156例孤立性颅脑损伤患者被送入ICU。其中,有203人(占18%)接受了β受体阻滞剂,而有953人(占82%)未接受。接受β受体阻滞剂的患者年龄较大(50 +/- 21岁,而38 +/- 20岁,p <0.001),更频繁发生严重的头部损伤(缩写为伤害评分>或= 4)(54%vs 43%,p <0.01),格拉斯哥昏迷评分小于或等于8(37%vs 47%,p = 0.01),颅骨骨折较多(20%vs 12%,p <0.01),并且颅骨切除术更频繁(23%vs 4) %,p <0.001)。逐步逻辑回归确定β-受体阻滞剂是死亡率的独立保护因素(调整后的优势比:0.54; 95%CI,0.33至0.91; p = 0.01)。在亚组分析中,严重颅脑损伤(缩写为伤害评分>或= 4)的老年患者(55岁或以上)在使用β受体阻滞剂时的死亡率为28%,而未接受β受体阻滞剂的患者为60%(几率: 0.3; 96%CI,0.1至0.6; p = 0.001)。结论:颅脑外伤患者的β受体阻滞独立地与生存改善相关。严重颅脑外伤的老年患者表现出最大的死亡率降低。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号